A US federal judge has denied Amgen Inc.'s request to halt Cipla Ltd.’s sales of a generic version of Sensipar (cinacalcet), ruling that Amgen is not likely to succeed on the merits of its breach of contract claim against the generic firm.
In a 2 May opinion, Chief Judge Leonard Stark of the US District Court for the District of Delaware concluded that the February 2018 patent settlement agreement between Amgen and Cipla precludes Amgen’s ability to seek relief for Cipla’s at-risk cinacalcet launch. This is because Teva Pharmaceutical Industries Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?